Five EMT‐related genes signature predicts overall survival and immune environment in microsatellite instability‐high gastric cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4975
Abstract: Microsatellite instability‐high (MSI‐H) subgroup of gastric cancer (GC) is characterized by a high tumor mutational burden, increased lymphocytic infiltration, and enhanced inflammatory cytokines. GC patients with MSI‐H status have a good response to immune checkpoint… read more here.
Keywords: microsatellite instability; instability high; gastric cancer; immune ... See more keywords
Mutations in Classical Signaling Pathways and Their Functional Impact in Microsatellite Instability High Colorectal Cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Genetic testing and molecular biomarkers"
DOI: 10.1089/gtmb.2022.0118
Abstract: Aims: Colorectal carcinomas with microsatellite instability high (MSI-H) are a distinctive group among colorectal cancers (CRCs). This study investigated the mutations of genes in the common signaling pathways and their potential clinical implications in MSI-H… read more here.
Keywords: microsatellite instability; classical signaling; instability high; mutations classical ... See more keywords
Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Science"
DOI: 10.1111/cas.15650
Abstract: The phase 3 KEYNOTE‐177 study evaluated pembrolizumab versus chemotherapy with or without bevacizumab or cetuximab in patients with newly diagnosed, microsatellite‐instability‐high (MSI‐H)/mismatch‐repair‐deficient (dMMR) metastatic colorectal cancer (mCRC). Primary endpoints were progression‐free survival (PFS) per RECIST… read more here.
Keywords: microsatellite instability; mismatch repair; instability high; repair deficient ... See more keywords
Abstract 4279: Method for identifying microsatellite instability high DNA abnormality samples
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4279
Abstract: Introduction: Tissue samples with high microsatellite instability (MSI-H) can be indicators of cancerous tumors that are sensitive to certain types of cancer treatments (e.g., immune modulation-checkpoint inhibitor treatment). MSI-H regions can be identified with Polymerase… read more here.
Keywords: msi; microsatellite instability; instability high; instability ... See more keywords
Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e15134
Abstract: e15134Background: We use a decision analytic model to project the effectiveness and cost burden of microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) treatment in the era of immunotherapy. Methods: We simulated the treatment… read more here.
Keywords: instability high; microsatellite instability; ipilimumab nivolumab; mismatch repair ... See more keywords
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.01351
Abstract: PURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in the neoadjuvant space. METHODS This is a phase II open-label, single-center trial… read more here.
Keywords: deficient mismatch; microsatellite instability; mismatch repair; instability high ... See more keywords
Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Future oncology"
DOI: 10.2217/fon-2017-0696
Abstract: Nivolumab is a PD-1 inhibitor approved for the use in treatment of multiple tumor types (such as melanoma, non-small-cell lung cancer, renal cell carcinoma, urothelial cancer and Hodgkin's lymphoma). In July 2017, the US FDA… read more here.
Keywords: metastatic colorectal; treatment; colorectal cancer; instability high ... See more keywords